Senores Pharmaceuticals
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Senores Pharmaceuticals is positioned for robust growth, driven by an aggressive product launch strategy and strategic capacity expansions. Management's focus on scaling its regulated market presence, particularly through the launch of 35 approved ANDAs in the US and over 500 products in emerging markets, supports a projected revenue CAGR of 35% over the next three years. The anticipated European PIC/S certification for the Chhatral facility will further enhance market access, contributing to a revenue target of INR 25–30 billion in the next three to four years. However, while the company is optimistic about achieving FY27E revenue growth of 30–40% and PAT growth of 50–60%, potential US tariffs on imported generics and a shift towards profitability-focused growth in branded generics may pose challenges. Vista's financial outlook reflects these dynamics, with expectations of continued revenue growth and margin pressure, aligning with a fair valuation. The overall industry context, characterized by improving pricing power and currency depreciation benefits, supports Senores' growth trajectory. Key opportunities include the successful commissioning of the Atlanta facility and the expansion into high-margin products, while watchpoints include regulatory compliance and market execution risks
Why We Like This Stock
- Aggressive product launch strategy with 35 approved ANDAs in the US and over 500 products in emerging markets
- Anticipated European PIC/S certification for the Chhatral facility, enhancing market access
- Strategic pivot towards higher-margin products and internalizing distribution to improve profitability
Things To Watch Out For
- Potential US tariffs on imported generic medicines could impact cost structures
- Shift towards profitability-focused growth in branded generics may slow short-term revenue expansion
- Execution risks associated with ramping up new commercial verticals in the US market
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 215 | 398 | 633 | 785 | 1,040 |
| Profit Before Tax (Cr.) | 25 | 71 | 159 | 227 | 290 |
| PBT Margin | 11.6% | 17.8% | 2511.8% | 29.0% | 27.8% |
| Net Profit (Cr.) | 17 | 55 | 140 | 198 | 242 |
| Earnings Per Share | 3.5 | 11.9 | 29.1 | 41.3 | 52.6 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Choice Equity | ▲ Buy | 1,795 | 28-Jul-2026 |
Company Overview
Show Company Profile
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.